RecruitingEarly Phase 1NCT06327269

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

Studying Fibrolamellar hepatocellular carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chang Gung Memorial Hospital
Intervention
Lenvatinib 10 mg(drug)
Enrollment
40 enrolled
Eligibility
18-75 years · All sexes
Timeline
20212026

Study locations (1)

Collaborators

Ministry of Health and Welfare, Taiwan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06327269 on ClinicalTrials.gov

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Fibrolamellar hepatocellular carcinoma

← Back to all trials